Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 2
2005 1
2006 2
2007 4
2008 4
2009 7
2010 1
2011 5
2012 4
2013 6
2014 13
2015 14
2016 27
2017 32
2018 25
2019 24
2020 30
2021 27
2022 27
2023 24
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

256 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Metastatic Malignant Pancreatic Neoplasm"
Page 1
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. Suker M, et al. Lancet Oncol. 2016 Jun;17(6):801-810. doi: 10.1016/S1470-2045(16)00172-8. Epub 2016 May 6. Lancet Oncol. 2016. PMID: 27160474 Free PMC article. Review.
BACKGROUND: 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. ...METHODS: We systematically searched Embase, MEDLINE (OvidSP), Web of Science, Scopus, PubMed Publisher, Cochrane, and Google Scholar from July 1, 1994, to July 2, …
BACKGROUND: 35% of patients with pancreatic cancer have unresectable locally advanced disease at diagnosis. ...METHODS: We systematic …
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Nichetti F, Rota S, Ambrosini P, Pircher C, Gusmaroli E, Droz Dit Busset M, Pusceddu S, Sposito C, Coppa J, Morano F, Pietrantonio F, Di Bartolomeo M, Mariani L, Mazzaferro V, de Braud F, Niger M. Nichetti F, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2350756. doi: 10.1001/jamanetworkopen.2023.50756. JAMA Netw Open. 2024. PMID: 38190183 Free PMC article.
IMPORTANCE: The NAPOLI 3 trial showed the superiority of fluorouracil, leucovorin, liposomal irinotecan, and oxaliplatin (NALIRIFOX) over the combination of gemcitabine and nab-paclitaxel (GEM-NABP) as first-line treatment of metastatic pancreatic ductal adenocarcin …
IMPORTANCE: The NAPOLI 3 trial showed the superiority of fluorouracil, leucovorin, liposomal irinotecan, and oxaliplatin (NALIRIFOX) over th …
Exercise for cancer cachexia in adults.
Grande AJ, Silva V, Sawaris Neto L, Teixeira Basmage JP, Peccin MS, Maddocks M. Grande AJ, et al. Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD010804. doi: 10.1002/14651858.CD010804.pub3. Cochrane Database Syst Rev. 2021. PMID: 33735441 Free PMC article.
We used standard methodological procedures expected by Cochrane. Our primary outcome was lean body mass and secondary outcomes were adherence to exercise programme, adverse events, muscle strength and endurance, exercise capacity, fatigue and health-related quality of life …
We used standard methodological procedures expected by Cochrane. Our primary outcome was lean body mass and secondary outcomes were a …
Comparison of different second line treatments for metastatic pancreatic cancer: a systematic review and network meta-analysis.
Petrelli F, Parisi A, Tomasello G, Mini E, Arru M, Russo A, Garrone O, Khakoo S, Ardito R, Ghidini M. Petrelli F, et al. BMC Gastroenterol. 2023 Jun 19;23(1):212. doi: 10.1186/s12876-023-02853-w. BMC Gastroenterol. 2023. PMID: 37337148 Free PMC article.
BACKGROUND: In metastatic pancreatic ductal adenocarcinoma (mPDAC), first line treatment options usually include combination regimens of folinic acid, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (FOLFIRINOX or mFOLFIRINOX) or gemcitabine based regimens such a …
BACKGROUND: In metastatic pancreatic ductal adenocarcinoma (mPDAC), first line treatment options usually include combination r …
Research advances and treatment perspectives of pancreatic adenosquamous carcinoma.
Zhang W, Zhang J, Liang X, Ding J. Zhang W, et al. Cell Oncol (Dordr). 2023 Feb;46(1):1-15. doi: 10.1007/s13402-022-00732-2. Epub 2022 Nov 1. Cell Oncol (Dordr). 2023. PMID: 36316580 Review.
BACKGROUND: As a malignant tumor, pancreatic cancer has an extremely low overall 5-year survival rate. Pancreatic adenosquamous carcinoma (PASC), a rare pancreatic malignancy, owns clinical presentation similar to pancreatic ductal adenocarcinom …
BACKGROUND: As a malignant tumor, pancreatic cancer has an extremely low overall 5-year survival rate. Pancreatic adeno …
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
Dayyani F, Macarulla T, Johnson A, Wainberg ZA. Dayyani F, et al. Cancer Treat Rev. 2023 Feb;113:102502. doi: 10.1016/j.ctrv.2022.102502. Epub 2022 Dec 29. Cancer Treat Rev. 2023. PMID: 36641880 Free article. Review.
INTRODUCTION: The aim of this review was to characterize the second- and later-line (2L) treatment landscape for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). METHODS: This systematic literature review (PROSPERO: CRD42021279753) involved searche …
INTRODUCTION: The aim of this review was to characterize the second- and later-line (2L) treatment landscape for patients with metastatic …
The clinical implication of minimally invasive versus open pancreatoduodenectomy for non-pancreatic periampullary cancer: a systematic review and individual patient data meta-analysis.
Uijterwijk BA, Kasai M, Lemmers DHL, Chinnusamy P, van Hilst J, Ielpo B, Wei K, Song KB, Kim SC, Klompmaker S, Jang JY, Herremans KM, Bencini L, Coratti A, Mazzola M, Menon KV, Goh BKP, Qin R, Besselink MG, Abu Hilal M; International Study Group on non-pancreatic periAmpullary CAncer (ISGACA). Uijterwijk BA, et al. Langenbecks Arch Surg. 2023 Aug 15;408(1):311. doi: 10.1007/s00423-023-03047-4. Langenbecks Arch Surg. 2023. PMID: 37581763 Free PMC article. Review.
BACKGROUND: Most studies on minimally invasive pancreatoduodenectomy (MIPD) combine patients with pancreatic and periampullary cancers even though there is substantial heterogeneity between these tumors. ...Primary outcomes were (90-day) mortality, and major morbidity (Cla …
BACKGROUND: Most studies on minimally invasive pancreatoduodenectomy (MIPD) combine patients with pancreatic and periampullary cancer …
Brain Metastasis from Pancreatic Cancer: Our Experience and Systematic Review.
De Stefano FA, Morell A, Marks K, Fernandez S, Smith G, Mayo T, Merenzon M, Shah AH, Eichberg DG, Luther E, Ivan ME, Komotar RJ. De Stefano FA, et al. World Neurosurg. 2022 Oct;166:e590-e598. doi: 10.1016/j.wneu.2022.07.060. Epub 2022 Jul 19. World Neurosurg. 2022. PMID: 35863644
Simultaneously, a retrospective analysis was conducted of patients who underwent neurosurgical evaluation and treatment for intracranial metastatic lesions from pancreatic origin at a single institution. RESULTS: The original literature search yielded 292 articles, …
Simultaneously, a retrospective analysis was conducted of patients who underwent neurosurgical evaluation and treatment for intracranial …
Pancreatic Nerve Sheath Tumors: a Single Institutional Series and Systematic Review of the Literature.
Javed AA, Wright MJ, Hasanain A, Chang K, Burkhart RA, Hruban RH, Thompson E, Fishman EK, Cameron JL, He J, Wolfgang CL, Weiss MJ. Javed AA, et al. J Gastrointest Surg. 2020 Apr;24(4):841-848. doi: 10.1007/s11605-019-04201-4. Epub 2019 Apr 2. J Gastrointest Surg. 2020. PMID: 30941687 Review.
INTRODUCTION: Improvement in imaging has resulted in frequent diagnosis of benign and premalignant pancreatic tumors. Pancreatic nerve sheath (PNS) tumors are one of the rarest pancreatic tumors. ...The literature review identified 49 studies reporting 54 pat …
INTRODUCTION: Improvement in imaging has resulted in frequent diagnosis of benign and premalignant pancreatic tumors. Pancreatic …
Pancreatic carcinosarcoma: An orthogonal analysis.
Fleming AM, Hendrick LE, Glazer ES, Murphy AJ, Dickson PV, Shibata D, Yakoub D, Deneve JL. Fleming AM, et al. Surgery. 2023 Oct;174(4):907-915. doi: 10.1016/j.surg.2023.06.039. Epub 2023 Jul 29. Surgery. 2023. PMID: 37524640
BACKGROUND: Pancreatic carcinosarcoma is a rare subtype of pancreatic cancer. There are no consensus guidelines regarding its treatment. ...Published data from the Surveillance, Epidemiology, and End Results database supported the current analysis regarding the inci …
BACKGROUND: Pancreatic carcinosarcoma is a rare subtype of pancreatic cancer. There are no consensus guidelines regarding its …
256 results